Follicular lymphoma: Management options in the era of targeted therapy

Current Treatment Options in Oncology

Volumn 6, Issue 4, 2005, Pages 297-308

  Peterson, Christopher G ^b   Kahl, Brad S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; HEMOGLOBIN; IBRITUMOMAB TIUXETAN; LACTATE DEHYDROGENASE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ACUTE LEUKEMIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FEVER; FATIGUE; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HUMAN; MAINTENANCE THERAPY; MULTIPLE MYELOMA; MYALGIA; MYELODYSPLASIA; PROGNOSIS; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; REVIEW; SIDE EFFECT; SKIN MANIFESTATION;

EID: 24044515507     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0034-x     Document Type: Review

References (42)

1. International Lymphoma Study Group: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project [abstract]. Blood. 1997, 89:3909-3918.
2. Fisher RI, LeBlanc M, Press OW, et al.: New treatment options have changed the natural history of follicular lymphoma. Blood. 2004, 104:168.
3. Decaudin D, Lepage E, Brousse N, et al.: Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients - a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999, 17:2499-2505.
4. Coiffier B, Bastion Y, Berger F, et al.: Prognostic factors in follicular lymphomas. Semin Oncol, 1993, 20:89-95.
5. Gallagher CJ, Gregory WM, Jones AE, et al.: Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986, 4:1470-1480.
6. Federico M, Vitolo U, Zinzani PL, et al.: Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi Blood 2000, 95:783-789.
7. Foussard C, Desablens B, Sensebe L, et al.: Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III to IV patients. The GOELAMS Group, France. Ann Oncol 1997, 8(Suppl 1):49-52.
8. Hermans J, Krol AD, van Groningen K, et al.: International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995, 86:1460-1463.
9. Solal-Celigny P, Roy P, Colombat P, et al.: Follicular lymphoma international prognostic index. Blood 2004, 104:1258-1265.
10. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
11. Coiffer B, Ketterer N, Haioun C, et al.: A multicenter, randomized phase II study of rituximab at two dosages in patients with relapsed or refractory intermediate or high-grade NHL or in elderly patients in first-line therapy. Blood 1997, 90:510a.
12. Piro LD, White CA, Grillo-Lopez AJ, et al.: Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999, 10:655-661.
13. Davis TA, White CA, Grillo-Lopez AJ, et al.: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999, 17:1851-1857.
14. Davis TA, Grillo-Lopez AJ, White CA, et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135-3143.
15. Colombat P, Salles G, Brousse N, et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97:101-106.
16. Witzig TE, Vukov AM, Habermann TM, et al.: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005, 23:1103-1108.
17. Berinstein NL, Grillo-Lopez AJ, White CA, et al.: Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998, 9:995-1001.
18. Hainsworth JD, Litchy S, Burris HA III, et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002, 20:4261-4267.
19. Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004, 103:4416-4423.
20. Webster K, Cella D: Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology (Huntingt) 1998, 12:697-714; discussion 714, 717, 721.
21. Hainsworth JD, Litchy S, Shaffer DW, et al.: Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1088-1095.
22. Gordan LN, Grow WB, Pusateri A, et al.: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005, 23:1096-1102.
23. Czuczman MS, Grillo-Lopez AJ, White CA, et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268-276.
24. Czuczman MS, Weaver R, Alkuzweny B, et al.: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22:4711-4716.
25. Hiddemann W, Forstpointer R, Kneba M, et al.: The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma: results of two prospective randomized studies of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2004, 104:50.
26. Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
27. Hochster HS, Weller EA, Ryan T, et al.: Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol. 2004, 22:558.
28. McLaughlin P, Rodrigues M, Hagemeister F, et al.: Stage IV Indolent lymphoma: A randomized study of concurrent vs. sequential use of FND chemotherapy and rituximab monoclonal antibody therapy with interferon maintenance. J Clin Oncol 2003, 22:564.
29. Witzig TE, Gordon LI, Cabanillas F, et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:2453-2463.
30. Witzig TE, Flinn IW, Gordon LI, et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:3262-3269.
31. Vose JM, Wahl RL, Saleh M, et al.: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000, 18:1316-1323.
32. Kaminski MS, Estes J, Zasadny KR, et al.: Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000, 96:1259-1266.
33. Kaminski MS, Zelenetz AD, Press OW, et al.: Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001, 19:3918-3928.
34. Davies AJ, Rohatiner AZ, Howell S, et al.: Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004, 22:1469-1479.
35. Gordon LI, Molina A, Witzig T, et al.: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase I/II study. Blood 2004, 12:4429-4431.
36. Press OW, Unger JM, Braziel RM, et al.: A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously un-treated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003, 102:1606-1612.
37. Kaminski MS, Tuck M, Estes J, et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441-449.
38. Gopal AK, Gooley TA, Maloney DG, et al.: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003, 102:2351-2357.
39. O'Connor O, Wright J, Moskowitz C, et al.: A multi-center experience with single agent bortezomib in non-Hodgkin's lymphoma reveals marked differences in subtype sensitivity to proteasome inhibition. Blood 2004, 204:174.
40. Goy A, Younes A, McLaughlin P, et al.: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675.
41. Hsu FJ, Caspar CB, Czerwinski D, et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 1997, 89:3129-3135.
42. Timmerman JM, Czerwinski DK, Davis TA, et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99:1517-1526.